...Sun-Yran Chang; Dah-Shyong Yu; Cheng-Ping Ma; Ming-Yi Liau The intravesical instillation of bacillus Calmette-Guérin (BCG) has proved to be an effective modality for prophylaxis of recurrent superficial bladder cancer and treatment of carcinoma in situ. The domestic BCG, named Taipei- NIPM, which...

...P.D.J. Vegt; F.M.J. Debruyne; A.P.M. van der Meijden In this overview, Bacillus Calmette-Guérin (BCG) immunotherapy in superficial bladder cancer items are discussed on which consensus has been reached and on which controversies exist. The evaluation of the optimal route of administration has shown...

..., instructions or products referred to in the content or advertisements. Biomarker Image analysis cytometry BTA test NMP assay Intravesical chemotherapy Bacillus Calmette-Guérin α-Interferon Marker lesion Gene transfer European Urology EurUrol 1997;31(suppl 1): 10 19 1602930 K.H. Kurth...

...Moshe Bolkier; Boaz Moskovitz; Yehoshua Ginesin; Dan Richter Levin The effect of distilled water on exfoliated tumor cells from transitional bladder carcinoma was compared to the effect of bacillus Calmette-Guérin (BCG; a nonspecific immunotherapeutic agent) dissolved in either saline or distilled...

...A. Morales In superficial bladder cancer, bacillus Calmette-Guérin (BCG) is effective in the prevention of tumour recurrences, in the destruction of papillary lesions and, particularly, in the eradication of carcinoma in situ. In comparative trials BCG is superior to chemotherapeutic agents. Recent...

...T.L. Ratliff Intravesical bacillus Calmette-Guérin (BCG) has been shown in prospective, randomized clinical trials to be the treatment of choice for superficial bladder cancer. In this treatment regimen, viable bacteria are introduced into the bladder, provoking an infection which induces...

...G. Jakse Bacillus Calmette-Guérin (BCG) is the most effective intravesical therapy of carcinoma in situ of the urinary bladder. Six, weekly instillations of BCG result in a complete remission in about 70-80% of patients. The optimal dose however has still to be defined, and the value of maintenance...

...L.M.H. Schreinemachers; A.P.M. van der Meijden; J. Wagenaar; P.A. Steerenberg; W.F.J. Feitz; D.G. Groothuis; R.H. Tiesjema; W.H. deJong; F.M.J. Debruyne; E.J. Ruitenberg In 30 patients toxic side effects of Bacillus Calmette-Guérin (BCG) were evaluated after intradermal and intravesical...

...Adolphe Steg; Christian Leleu; Bernard Debré; Laurent Boccon-Gibod; Didier Sieard Among 169 patients treated for supeficial bladder tumor with 150 mg Pasteur-strain bacillus Calmette-Guérin (BCG) intravesical instillation, 5 cases of ‘BCGitis’ were observed, i.e. a severe systemic BCG infection...

... such as shape change, adherence, exocytosis and respiratory burst, events that are of importance in inflammation. To study the release of NAP-1/IL-8, two human models of inflammation were chosen: transurethral resection of superficial bladder cancer and the subsequent instillation of bacillus Calmette-Guérin...

...E. Rintala; K. Jauhiainen; O. Alfthan; E. Hansson; H. Juusela; K. Kanerva; H. Korhonen; J. Permi; M. Sotarauta; T. Vaalasti; J. Viitanen; R. Usenius Both intravesical mitomycin C (MMC) and bacillus Calmette-Guérin (BCG; Pasteur strain F) were effective in the present prospective randomized...

...A. Böhle; J. Schüller; A. Knipper; A. Hofstetter 14 patients with radiologically documented vesicorenal reflux (5 bilateral, 7 unilateral, 2 unilateral double-J stents) received intravesical immunotherapy with bacillus Calmette-Guérin (BCG) after treatment of their superficial urothelial tumors. 1...

...Sven Brandau; Andreas Böhle Objectives: Using a human in vitro model we have previously identified so–called bacillus Calmette–Guérin (BCG)–activated killer (BAK) cells as potential effector cells in BCG immunotherapy. This study was designed to prove the hypothesis that BAK cells...

...Norio Nonomura; Yutaka Ono; Masahiro Nozawa; Tatsunari Fukui; Yasunori Harada; Kazuo Nishimura; Natsuki Takaha; Shiro Takahara; Akihiko Okuyama Objectives: The aim of this study is to evaluate the efficacy and safety of intrarenal bacillus Calmette–Guérin (BCG) instillation as a treatment...

.... Further studies are necessary to define the precise role of KLH in patients with CIS. Keyhole limpet hemocyanin Bacillus Calmette-Guérin Carcinoma in situ The natural history of carcinoma in situ (CIS) of the bladder and its malignant potential are extremely variable, but progression...

...C. Durek; S. Rüsch-Gerdes; D. Jocham; A. Böhle The viability of bacillus Calmette-Guérin (BCG) in intravesical instillation therapy has been demonstrated to be crucial for the prevention of bladder tumour recurrence. The aim of the present study was to determine the effects of modern antibacterial...

...A.P.M. van der Meijden; R.R. Hall; M. Pavone Macaluso; A. Pawinsky; R. Sylvester; M. van Glabbeke Objectives: To study the ablative activity of intravesical mitomycin C followed by intravesical bacillus Calmette-Guérin (BCG) on a papillary marker tumour and to determine the incidence of side...